Editorial

"RegenLab, Long Island University, Dassault Systèmes are committed to the development regenerative medicine research."

Regen Lab is a leading industrial innovator of medical devices for autologous regenerative medicine, based on the extemporaneous preparation of platelet-rich plasma (PRP, autologous thrombin, etc.) from patient blood, cell therapy (notably the extraction of MSC from bone marrow) and combination therapy (PRP combined with hyaluronic acid).
To date, Regen Lab's patented technologies are available in over 160 countries worldwide, and have been used to treat over 2 million patients in various therapeutic areas (musculoskeletal, dermal, wound care and intimacy), resulting in the publication of over 200 research projects.
With the installation of Regen Lab in Saclay, France, and in New York, USA, essential links are being developed with multidisciplinary university research teams from Long Island University (LIU) and leading French and American teams brought together by Dassault Systèmes (France & US).
With the installation of Regen Lab in Saclay, France, and in New York, USA, essential links are being developed with multidisciplinary university research teams from Long Island University (LIU) and leading French and American teams brought together by Dassault Systèmes (France & US).
A dynamic strategy has been drawn up for the next 5 years, which includes the following R&D priorities, rich in potential. Investment highlights include the following.
For a world-leading, profitable and prolific tissue engineering specialist like Regen Lab, here are the key transformative growth opportunities over the next five years:
1/ An integrated tissue engineering engine from intellectual property to manufacturing.
2/ Solid marketing experience backed by a profitable global portfolio.
3/ A solid reserve of incremental innovation and transformation opportunities.
4/ A compact team of tissue engineering experts.
en_US